CD8A and neoplasm: Incorporating adenoviral and self-amplifying mRNA vectors encoding the top 20 predicted neoantigens, a personalized neoantigen vaccine regimen aims at induce tumor-specific CD8+ T cell responses and improve PFS in mCRC patients [416].